Drug class in one race
HER2 drugs for Non-Small Cell Lung Cancer
13 tracked HER2 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the HER2 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 42 Phase 34 Phase 24 Phase 11 preclinical / unstaged
Head-to-head evidence: 177Lu-DWJ155 vs Disitamab Vedotin · BL-M07D1 vs Disitamab Vedotin · BL-M17D1 vs Disitamab Vedotin · Disitamab Vedotin vs HRS-4508 · Disitamab Vedotin vs KJ015 · Disitamab Vedotin vs MT-304